Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak

FOSTER CITY, Calif., March 25, 2020 /3BL Media/ – For those with potentially immunosuppressing conditions, such as HIV, the uncertainty caused by the novel coronavirus pandemic can be particularly challenging. Gilead remains focused on ensuring that people living with or at risk for HIV have access to the medications and support needed.

Gilead’s global commercial supply chain is robust and resilient with the right processes in place, geographic diversity in our supply chain and enough of the materials required to make our medicines. We have done this purposefully and carefully to enable continued supply of Gilead’s medicines in a challenging situation like the one we face today. As a result, we are not seeing, and we do not anticipate, shortages of Gilead marketed products, including our HIV treatment or prevention medicines, in the foreseeable future.

Our supply network provides both flexibility and redundancy, and our inventory levels are robust, with no immediate or forseesable risk to our supply chain. For more information, please see this article. We are also working closely with our partners to monitor travel restrictions and border closings. There are currently no restrictions or delays limiting the transport of goods, including medications.

We are contributing our antiviral expertise and resources to help communities respond to the novel coronavirus outbreak and can assure our partners, healthcare providers, and the people we serve that our medications will continue to be available.

For those living with HIV who may have questions related to their risk for COVID-19 and the need to maintain a daily treatment regimen, the Centers for Disease Control and Prevention has recently published guidance, including:

• People living with HIV should continue taking medicines as advised by their healthcare provider;
• Have at least a 30-day supply of your HIV medicine and any other medications or medical supplies you need for managing HIV; and
• Establish a plan for clinical care if you have to stay at home for a couple of weeks, which means ensuring you can communicate with your healthcare provider by phone or text.

About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.